TY - CHAP M1 - Book, Section TI - Pediatric Sickle Cell Disease A1 - Strouse, John J. A1 - S. Green, Nancy A2 - Gladwin, Mark T. A2 - Kato, Gregory J. A2 - Novelli, Enrico M. PY - 2021 T2 - Sickle Cell Disease AB - Morbidity and mortality in pediatric sickle cell disease (SCD) in the United States have markedly declined since the 1970s. Initial impact from newborn screening for presymptomatic diagnosis, early initiation of preventative care, and widespread initiation of disease-modifying therapies have led to reduced early mortality and reduced childhood morbidities. Nonetheless, several specific complications remain that are partially or entirely specific to pediatric SCD. Persistence of these complications is related to their early onset and structural and physiologic factors, especially dactylitis and splenic sequestration. Moreover, children with SCD remain especially susceptible to bacterial infections, likely due to early and ongoing decreases in splenic function. Here, we highlight the historical implementation of newborn screening for SCD and disease complications that exclusively or predominately affect children. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - hemonc.mhmedical.com/content.aspx?aid=1179344091 ER -